nesiritide sold brand name natrecor recombinant form amino acid human btype natriuretic peptide normally produced ventricular myocardium nesiritide works facilitate cardiovascular fluid homeostasis counterregulation system stimulating cyclic guanosine monophosphate leading smooth muscle cell relaxation nesiritide believed initially beneficial acute decompensated congestive heart failure received approval united states food drug administration purpose initial nonapproval july results largest study far nesiritide published new england journal medicine study failed show difference nesiritide placebo mortality nesiritide administered intravenously usually bolus followed iv infusion adults elderly normal dosage mgkg followed continuous iv infusion mgkgmin may increased every three hours maximum mgkgmin several academic papers published jonathan efficacy side effects nesiritide johnson johnson met fda altered stated plans drug agreed revise heart doctors cleveland clinic voted unanimously permit prescription drug johnson johnson convened panel experts whose advice included recommendation conduct largescale clinical trial subsequently published following united states department justice announced inquiry marketing led fine scios unit common side effects include rare side effects include drug article relating cardiovascular system stub help wikipedia expanding httpsenwikipediaorgwikinesiritide